secwatch.observer — SEC 8-K summary
======================================

Issuer:     RAPT Therapeutics, Inc. (—)
CIK:        0001673772
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056297
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RAPT closes Phase 2b/2a trials after FDA hold due to liver failure SAE; Q1 net loss $30.5M
--------------------------------------------------------------------------------

- Company to close and unblind Phase 2b atopic dermatitis and Phase 2a asthma trials of zelnecirnon following FDA clinical hold.
- Clinical hold triggered by one patient liver failure requiring transplant; 229 patients enrolled in AD trial.
- Net loss of $30.5M for Q1 2024 vs $29.3M in Q1 2023; cash and equivalents $141.6M.
- Data analysis from AD trial expected Q3 2024 to inform development path and FDA discussions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1673772/000095017024056297/0000950170-24-056297-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1673772/000095017024056297/rapt-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056297

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer